Bio-Techne (MIL:1TECH) Total Equity: €1,804 Mil (As of Mar. 2026)


MIL:1TECH Bio-Techne Corp MIL:1TECH
61 GF Score
Price €62.06
GF Value €63.40
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Total Equity?

Bio-Techne MIL:1TECH -0.70% 61 Total Equity is €1,804 Mil as of Mar. 2026. GuruFocus rates MIL:1TECH with a GF Score™ of 61/100 and a GF Value™ of €63.40 (Fairly Valued). The stock has 8 warning signs investors should review.

Bio-Techne's total equity for the quarter that ended in Mar. 2026 was €1,804 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bio-Techne Total Equity Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Total Equity Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,304.12 1,609.16 1,815.09 1,921.96 1,663.61

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,866.67 1,663.61 1,674.87 1,717.39 1,803.79
MIL:1TECH
61GF Score
Bio-Techne Corp MIL:1TECH
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bio-Techne's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=2217.672-554.065
=1,664

Bio-Techne's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2206.27-402.482
=1,804

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,804 Mil mean?
Bio-Techne (MIL:1TECH) has a Total Equity of €1,804 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bio-Techne and its competitors.
Is Bio-Techne's Total Equity too high?
Bio-Techne's current Total Equity is €1,804 Mil. Overall, Bio-Techne has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Total Equity compare to ARWR and CYTK?
Bio-Techne's Total Equity of €1,804 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bio-Techne and its competitors. Bio-Techne's current Total Equity is €1,804 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Fairly Valued. The stock's GF Value™ is €63.40, compared to a current price of €62.06 — trading 2.1% below its estimated fair value. The current Total Equity is €1,804 Mil. Bio-Techne's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Total Equity is €1,804 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MIL:1TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.06 is trading 2.1% below its estimated GF Value™ of €63.40. GuruFocus considers Bio-Techne to be Fairly Valued.

Key valuation signals for MIL:1TECH:

  • Total Equity: €1,804 Mil
  • GF Value™: €63.40 vs. price of €62.06 (2.1% below fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
61GF Score

Get the complete analysis for MIL:1TECH

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.06
Price
€63.40
GF Value